Guest: Warner K. Huh, MD

While the prevalence of cervical cancer in the population has decreased over the years, there are still 12,820 new cases and 4,210 deaths estimated in 2017; however, despite this progress, there remains marked uncertainty among healthcare providers regarding the optimal screening strategy for cervical cancer. While both primary high-risk HPV testing and cotesting approaches are known to be superior to cytology-alone, current evidence suggests that many patients as well as providers continue to favor cytology-based testing annually. Healthcare providers thus face challenges in integrating cotesting and primary high-risk HPV testing in clinical practice, or choosing one over the other for individual patients. The case presented in this CME activity addresses some of the issues faced by clinicians when selecting cervical cancer screening strategies for their patients.